Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said Craig Tendler, M.D., Vice President, Clinical Development and Global Medical Affairs, Janssen Research &Development, LLC. “This year, we look forward to presenting data from our robust prostate cancer development program, including analyses of the Phase 3 ACIS and TITAN studies, which underscore the clinical value of our portfolio for patients today and set the stage for the next generation of therapies in our pipeline.”New Analyses for ERLEADA® Highlight Breadth of Ongoing Clinical Development ProgramData from three Phase 3 registrational clinical trials will be featured in oral presentations:ACIS: Analysis evaluating ERLEADA® (apalutamide) in combination with ZYTIGA® (abiraterone acetate) plus prednisone versus abiraterone acetate plus prednisone in patients with chemo-naïve metastatic castration-resistant prostate cancer (Ab...
Authors: Rombauts A, Abelenda-Alonso G, Cuervo G, Gudiol C, Carratalà J Abstract INTRODUCTION: Despite adequate antibiotic coverage, community-acquired pneumonia (CAP) remains a leading cause of hospitalization and mortality worldwide. It induces both a local pulmonary and a systemic inflammatory response, particularly significant in severe cases. The intensity of the dysregulated host response varies from patient to patient and has a negative impact on survival and other outcomes. AREAS COVERED: This comprehensive review summarizes the pathophysiological aspects of the inflammatory response in CAP, brie...
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part BAuthor(s): Yanhua Liu, Yang Li, Shanshan Dong, Lu Han, Ruixin Guo, Yourong Fu, Shenghu Zhang, Jianqiu Chen
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part AAuthor(s): Cheng Han, Yinping Zhang, Marc Redmile-Gordon, Huan Deng, Zhenggui Gu, Qiguo Zhao, Fang Wang
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part AAuthor(s): Peter A. Bain, Adrienne Gregg, Alok K. Pandey, Mohana Krishna Reddy Mudiam, Peta A. Neale, Anu Kumar
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part AAuthor(s): Jinquan Chen, Xuan Li, Wei Jia, Shili Shen, Shengjiong Deng, Bohua Ji, Junjun Chang
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part BAuthor(s): Jinsoo Lee, Seong-Jin Choi, Ji-Seong Jeong, Sang Yun Kim, Sang-Hyub Lee, Mi Jin Yang, Seung-Jin Lee, Young-Jun Shin, Kyuhong Lee, Eun Ju Jeong, Sang-Yoon Nam, Wook-Joon Yu
Publication date: Available online 30 September 2020Source: Journal of Hazardous MaterialsAuthor(s): Anthony Beauvois, Delphine Vantelon, Jacques Jestin, Martine Bouhnik-Le Coz, Charlotte Catrouillet, Valérie Briois, Thomas Bizien, Mélanie Davranche
We describe the most highly recommended generic and disease-specific PRO tools in SCD and discuss the challenges of incorporating them in clinical practice. EXPERT OPINION: PRO measures are essential to incorporate into SCD clinical trials either as primary or secondary outcomes. The use of PRO measures in SCD facilitates a patient-centered approach, which is likely to lead to improved outcomes. Significant challenges remain in adapting PRO tools to routine clinical use and in developing countries. PMID: 33034214 [PubMed - as supplied by publisher]
Authors: Musio F Abstract INTRODUCTION: Anemia has and will continue to be a central theme in medicine particularly as clinicians are treating a burgeoning population of complex multi-organ system processes. As a result of multiple randomized controlled trials (RCTs), meta-analyses, and societal recommendations overly restrictive paradigms and under-administration of erythropoiesis stimulating agents (ESAs) have likely been followed by clinicians among all specialties. AREAS COVERED: A review of anemia in the context of chronic kidney disease, hematologic malignancies and cancer is presented with focus on the e...
More News: Abiraterone Acetate | Actos | Adrenocortical Carcinoma | Allergy & Immunology | Alopecia | Anemia | Arrhythmia | Bilirubin | Biotechnology | Brain | Breast Cancer | Breast Carcinoma | Breastfed | Calcium | Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Cardiology | Cardiovascular | Chemistry | Chemotherapy | Child Development | Children | Clinical Trials | Congestive Heart Failure | Constipation | Corticosteroid Therapy | Cough | Diabetes | Docetaxel | Drugs & Pharmacology | Endocrinology | Epilepsy | Epithelial Cancer | Fallopian Tube Cancer | Fundoscopy | Gastroschisis Repair | Genetics | Headache | Health Management | Heart | Heart Attack | Heart Disease | Heart Failure | Hematology | Hepatitis | Hepatitis Vaccine | Hepatocellular Carcinoma | Hormonal Therapy | Hormones | Hypertension | Hypothyroidism | Infectious Diseases | Japan Health | Ketoconazole | Laboratory Medicine | Learning | Legislation | Liver | Liver Cancer | Magnesium | Migraine | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Neurology | Neuroscience | Onycholysis | Opthalmology | Oral Cancer | Organic | Orthopaedics | Ovarian Cancer | Ovaries | Pain | Pain Management | Peritoneal Cancer | Pharmaceuticals | Prednisolone | Prednisone | Pregnancy | Pregnancy and Breast Cancer | Profits and Losses | Prostate Cancer | Prostatectomy | Pulmonary Hypertension | Radiation Therapy | Reflex Sympathetic Dystrophy | Reproduction Medicine | Respiratory Medicine | Science | Serous Carcinoma | Skin | Sodium | Statistics | Study | Taxotere | Thyroid | Thyroid Cancer | Toxicology | Universities & Medical Training | Urology & Nephrology | Vaccines | Ventricular Arrhythmia | Veterinary Vaccinations | Vitamin A | Warnings | Women